Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Murdoch University manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The data shows 2 pending office actions currently in progress. These actions are being handled by 2 distinct examiners. Furthermore, the prosecution is occurring across 2 distinct art units, indicating that each pending matter is being treated as a separate technical and administrative entity within the patent office. This distribution suggests that the Biotechnology & Pharmaceuticals innovations currently under review are diverse enough to be assigned to different specialized units.
The busiest examiner for Murdoch University is SIFFORD, JEFFREY MARK, who has 1 busiest examiner pending action. With a total of 2 pending office actions, the workload is split between SIFFORD, JEFFREY MARK and 1 other distinct examiner. This distribution means that no single examiner dominates the current prosecution landscape. For a practitioner, this requires navigating the specific requirements of 2 distinct art units and the individual tendencies of 2 different examiners. The lack of overlap in examiners or art units suggests that the 2 pending office actions may involve distinct technological applications within the broader field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SIFFORD, JEFFREY MARK | 1 | 55.1% | +32.8% |
| HYUN, PAUL SANG HWA | 1 | 69.8% | +36.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18628273 | MEANS AND METHODS FOR DIAGNOSING A VIRAL INFECTION OR A DISEASE ASSOCIATED THEREWITH | SIFFORD, JEFFREY MARK | — |
| 18262262 | INFECTION DIAGNOSIS AND CHARACTERIZATION USING DIFFUSION AND RELAXATION EDITED PROTON NMR SPECTROSCOPY | HYUN, PAUL SANG HWA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18628273 | MEANS AND METHODS FOR DIAGNOSING A VIRAL INFECTION OR A DISEASE ASSOCIATED THEREWITH | SIFFORD, JEFFREY MARK | — |
| 18262262 | INFECTION DIAGNOSIS AND CHARACTERIZATION USING DIFFUSION AND RELAXATION EDITED PROTON NMR SPECTROSCOPY | HYUN, PAUL SANG HWA | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| 1796 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18628273 | MEANS AND METHODS FOR DIAGNOSING A VIRAL INFECTION OR A DISEASE ASSOCIATED THEREWITH | SIFFORD, JEFFREY MARK | 1671 | §103§112 | Non-Final OA | — | Pending | Apr 05, 2024 |
| 18262262 | INFECTION DIAGNOSIS AND CHARACTERIZATION USING DIFFUSION AND RELAXATION EDITED PROTON NMR SPECTROSCOPY | HYUN, PAUL SANG HWA | 1796 | §101§102§112 | Non-Final OA | — | Pending | Jul 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMurdoch University has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Jeffrey Mark Sifford has the most, with 1 of Murdoch University's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
